Honokiol: A potent chemotherapy candidate for human colorectal carcinoma

Table 1 Effect of honokiol on cell cycle distribution and apoptosis of RKO cells

Groups	Cell cycle distribution (%)			Apoptosis (%)
	G0/G1	S	G2/M
ControL	44.45	45.10	10.14	0.27
5 μg/mL	48.03	42.37	9.60	4.51
10 μg/mL	54.04	40.30	5.66	14.10a
15 μg/mL	58.94	39.36	1.70	20.31b

^aP < 0.05,

^bP < 0.01 vs corresponding control group. Cell cycle distribution was determined after 48 h of treatment in each group. The tabulated percentages were an average calculated on the results of three separate experiments. The results were represented by mean ± SD (n = 3).

Table 2 Effect of honokiol on ascites growth of tumor in Babl/ c nude mice

Group	Ascites	MST(d)	Dead(D)	Living(L)	Survival percentage(L/(D + L) × 100%)
Control	5	10.7	5	0	0%
Honokiol	1	34.3	1	4	80%

MST: Mean survival time. RKO cells were transplanted intraperitoneally. Honokiol was administered 2 mg per mice on d 0, 2, 4, 6, 8, and 10 after tumor transplantation. The mice were monitored for peritoneal bulge and survived for up to 30 d. Control mice died by d 12 of RKO inoculation.

Table 3 Effect of honokiol on MST and T/C% in Balb/c nude mice bearing RKO-incubated tumor

Group	Number of mice	MST (d)	T/c (%)
Control	7	28.8	100
Vehicle	6	29.7	104.5
Adriamycin	7	46.2a	160.4b
Honokiol	7	50.9a	176.7b

MST, mean survival time. The survival rate (T/C%) was cal-culated according to the following equation: T/C (%) = [average survival period in the test group/average survival period in the control group] × 100.

^aP < 0.05;

^bP < 0.01 vs vehicle or control.